Trinity Biotech reported $35.9M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Bio-Rad Laboratories USD 3.02B 78.4M Jun/2026
EDAP TMS EUR 50.36M 6.01M Mar/2026
J&J USD 59.77B 601M Jun/2026
Mesa Laboratories USD 105.63M 8.2M Dec/2025
OraSure Technologies USD 240.78M 21.13M Mar/2026
Plus Therapeutics USD 18.03M 2.86M Mar/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Siemens EUR 68.95B 1.04B Mar/2026
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
Tosoh JPY 835.36B 37.3B Jun/2026
Trinity Biotech USD 35.9M 382K Dec/2025
Veracyte USD 574.78M 52.6M Jun/2026